In its upcoming report, IQVIA Holdings (IQV) is predicted by Wall Street analysts to post quarterly earnings of $3.40 per share, reflecting an increase of 9% compared to the same period last year. Revenues are forecasted to be $4.24 billion, representing a year-over-year increase of 7.2%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific IQVIA metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenues- Technology & Analytics Solutions' reaching $1.77 billion. The estimate suggests a change of +6.9% year over year.
Analysts expect 'Revenues- Research & Development Solution' to come in at $2.29 billion. The estimate indicates a year-over-year change of +7.7%.
The collective assessment of analysts points to an estimated 'Revenues- Contract Sales & Medical Solutions' of $193.15 million. The estimate points to a change of +9.1% from the year-ago quarter.
According to the collective judgment of analysts, 'Backlog' should come in at $32.57 billion. Compared to the present estimate, the company reported $31.10 billion in the same quarter last year.
The combined assessment of analysts suggests that 'Segment Profit- Technology & Analytics Solution' will likely reach $449.80 million. The estimate is in contrast to the year-ago figure of $421.00 million.
The average prediction of analysts places 'Segment Profit- Contract Sales & Medical Solutions' at $7.78 million. The estimate compares to the year-ago value of $13.00 million.
Analysts predict that the 'Segment Profit- Research & Development Solutions' will reach $510.90 million. Compared to the present estimate, the company reported $478.00 million in the same quarter last year.
View all Key Company Metrics for IQVIA here>>>
IQVIA shares have witnessed a change of -1.4% in the past month, in contrast to the Zacks S&P 500 composite's +1.8% move. With a Zacks Rank #2 (Buy), IQV is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IQVIA Holdings Inc. (IQV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
